Rate of Recurrence of Non-Small Cell Lung Cancer in Patients Treated with Percutaneous Ablation


Background: Percutaneous ablation therapy as a treatment for non-small cell lung cancer (NSCLC) has been increasingly utilized. There is little data on long term efficacy. Because of this we reviewed the rate of recurrence of all ablation procedures done at our institution for the last 6 years. Methods: A total of 36 patients underwent 43 percutaneous procedures from July 2008 until January 2014 at our institution. There were 9 patients treated with radiofrequency ablation (RFA) and 27 treated withmicrowave ablation (MWA) for Stage I NSCLC. Each patient was reviewed to determine if there was a recurrence, the time to recurrence and the characteristics of the original cancer possibly predisposing the procedure to failure. Results: There were 8 recurrences in 9 patients undergoing RFA occurring at a median time of 842 days (range 425 - 1568) after their procedure. MWA was utilized in 27 patients for 34 procedures with 11 patients experiencing recurrences at a median time of 487 days (range 168 - 845). The median follow up time for the RFA patients was 1631 days (4.46 years) and for the MWA patients 751 days (2.06 years). Of the RFA recurrences, 5 involved systemic spread of their cancer and 3 were limited to site recurrences only. Of the MWA recurrences, 5 involved systemic spread of their cancer, 2 had chest wall recurrences and 4 were limited to site recurrences only.

Share and Cite:

S. Regmi, N. , Heber, B. and W. Klena, J. (2014) Rate of Recurrence of Non-Small Cell Lung Cancer in Patients Treated with Percutaneous Ablation. Advances in Lung Cancer, 3, 75-81. doi: 10.4236/alc.2014.34011.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Alexander, E.S. and Dupuy, D.E. (2013) Lung Cancer Ablation: Technologies and Techniques. Seminars in Interventional Radiology, 30, 141-150. http://dx.doi.org/10.1055/s-0033-1342955
[2] Zhu, J.C., Yan, T.D. and Morris, D.L. (2008) A Systemic Review of Radiofrequency Ablation for Lung Tumors. Annals of Surgical Oncology, 15, 1765-1774. http://dx.doi.org/10.1245/s10434-008-9848-7
[3] Yamamoto, K., Ohsumi, A., Kojima, F., Imanishi, N., Matsuoka, K., Ueda, M. and Miyamoto, Y. (2010) Long Term Survival after Video-Assisted Thoracic Surgery Lobectomy for Primary Lung Cancer. Annals of Thoracic Surgery, 89, 353-359. http://dx.doi.org/10.1016/j.athoracsur.2009.10.034
[4] Pennathur, A., Abbas, G., Gooding, W.E., Schuchert, M.J., Gilbert, S., Christie, N.A., et al. (2009) Image-Guided Radiofrequency Ablation of Lung Neoplasm in 100 Consecutive Patients by a Thoracic Surgery Service. Annals of Thoracic Surgery, 88, 1601-1608.
[5] De Baere, T., Farouil, G. and Deschamps, F. (2013) Lung Cancer Ablation: What Is the Evidence? Seminars in Interventional Radiology, 30, 151-156. http://dx.doi.org/10.1055/s-0033-1342956
[6] Charlson, M.E., Pompei, P., Ales, K.L. and MacKenzie, C.R. (1987) A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies. Development and Validation. Journal of Chronic Diseases, 40, 373-383. http://dx.doi.org/10.1016/0021-9681(87)90171-8
[7] Vogl, T.J., Worst, T.S., Naguib, N.N., Ackerman, H., Gruber-Rouh, T. and Nour-Eldin, N.A. (2013) Factors Influencing Local Tumor Control in Patients with Neoplastic Pulmonary Nodules Treated with Microwave Ablation: A Risk-Factor Analysis. American Journal of Roentgenology, 200, 665-672.
[8] Birchard, K.R., Hoang, J.K., Herndon Jr., J.E. and Patz Jr., E.F. (2009) Early Changes in Tumor Size in Patients Treated for Advanced Stage Nonsmall Cell Lung Cancer Do Not Correlate with Survival. Cancer, 115, 581-586. http://dx.doi.org/10.1002/cncr.24060
[9] American Cancer Society. Cancer Facts and Figures 2014.
[10] Baisi, A., De Simone, M., Raveglia, F. and Cioffi, U. (2012) Thermal Ablation in the Treatment of Lung Cancer: Present and Future. European Journal of Cardio-Thoracic Surgery, 43, 683-686.
[11] Greene, F.L., Page, D.L., Fleming, I.D., et al. (2002) AJCC Cancer Staging Manual 6th Edition, Springer, New York, 107-181.
[12] A Profile of Older Americans: 2002. (2002-2003) Administration on Aging, Washington DC.
[13] Henschke, C.I., Yankelevitz, D.F., Libby, D.M., et al. (2006) Survival of Patients with Stage I Lung Cancer Detected on CT Screening. New England Journal of Medicine, 355, 1763-1771.
[14] Henschke, C.I., Wisnivesky, J.P., Yankelevitz, D.F. and Miettinen, O.S. (2003) Small Stage I Cancers of the Lung: Genuineness and Curability. Lung Cancer, 39, 327-330.
[15] Raz, D.J., Zell, J.A., Ou, S.H., Gandara, D.R., Anton-Culver, H. and Jablons, D.M. (2007) Natural History of Stage I Non-Small Cell Lung Cancer: Implications for Early Detection. Chest Journal, 132, 193-199.
[16] Landreneau, J.P., Schuchert, M.J., Weyant, R., Abbas, G., Wizorek, J.J., Awais, O., et al. (2014) Anatomic Segmentectomy and Brachytherapy Mesh Implantation for Clinical Stage I Non-Small Cell Lung Cancer. Surgery, 155, 340- 346. http://dx.doi.org/10.1016/j.surg.2013.06.055
[17] Howington, J.A., Blum, M.G., Chang, A.C., Balekian, A.A. and Murthy, S.C. (2013) Treatment of Stage I and Stage II Non-Small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 143, 278-313.
[18] Wolf, F.J., Grand, D.J., Machan, J.T., DiPetrillo, T.A., Mayo-Smith, W.W. and Dupuy, D.E. (2008) Microwave Ablation of Lung Malignancies: Effectiveness, CT Findings, and Safety in 50 Patients. Radiology, 247, 871-879. http://dx.doi.org/10.1148/radiol.2473070996
[19] Deslauriers, J. (2012) Mediastinal Lymph Node Metastases: Ignore? Sample? Dissect? The Role of Mediastinal Node Dissection in the Surgical Management of Primary Lung Cancer. General Thoracic and Cardiovascular Surgery, 60, 724-734. http://dx.doi.org/10.1007/s11748-012-0086-3

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.